329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib

Jonathan W. Riess, H.A. Yu, Z. Piotrowska et al.|Annals of Oncology|2022

Cited by 4